Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promotion of sexual health and HPV vaccination program in middle schools
2020-002332-73Phase 4Completed
- Sponsor
- CHU de La Réunion
- Start
- Jul 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), anogenital warts and 4 more, sponsored by CHU de La Réunion. Primary endpoint: HPV vaccination uptake. Started Jul 2020; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital wartsanal cancerVulval carcinoma
Beyond the preview
Go deeper on 2020-002332-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002332-73.